Related Experiment Video
Updated: Jul 9, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Into the light: strategies for battling hepatitis C
Bruce R Bacon1, John G McHutchison
1Division of Gastroenterology and Hepatology, Saint Louis University, 3635 Vista Ave, FDT 9th Fl S, St. Louis, MO 63110, USA. baconbr@slu.edu
The American Journal of Managed Care
|January 12, 2008
Summary
Hepatitis C virus (HCV) therapy aims for sustained virologic response (SVR). Combination therapy with peginterferon and ribavirin is standard, with higher SVR rates for genotypes 2 and 3 than genotype 1.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Hepatitis C virus (HCV) infection management focuses on achieving a sustained virologic response (SVR).
- Treatment decisions are influenced by infection severity, treatability, contraindications, and patient preferences.
Purpose of the Study:
- To outline the current standard of care for HCV therapy.
- To discuss treatment considerations based on viral genotype and previous treatment history.
- To highlight potential challenges and future directions in HCV treatment.
Main Methods:
- Combination therapy with pegylated interferon (peginterferon) and ribavirin is the current standard.
- Dosages and treatment duration are tailored to the specific hepatitis C viral genotype.
Main Results:
- SVR rates are higher for genotypes 2 and 3 (70%-80%) compared to genotype 1 (40%-50%).
- Retreatment with peginterferon and ribavirin is recommended for patients who previously failed other HCV therapies.
Conclusions:
- Effective management of side effects is crucial for patient adherence.
- Newer pharmacologic agents are under development for treatment-resistant or relapsed HCV cases.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...